skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
Searching for the latest up-to-date and accurate data on healthcare trends and healthcare industry challenges? Turn to Informa Pharma Intelligence. With coverage spanning the whole of the healthcare industry, you'll find essential information surrounding healthcare industry trends, including healthcare technology trends, healthcare insurance trends, and healthcare marketing trends.

O2 Outlook Report Extract

Get a reliable and accurate view into what’s on the horizon and inform your strategy and decision-making with the Biomedtracker Q2 2018 Outlook Report; it includes each drug’s likelihood of phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group.

Extracts from this important report includes:
  • Anticipated top-line data readouts
  • Information about upcoming FDA Advisory Committee meetings
  • Data on FDA approvals for drugs in various therapeutic areas
Biomedtracker - Q2 Outlook Report

A Review of Select Catalysts from Last Quarter’s Outlook Report

For a look at the outcome of two catalysts featured in Biomedtracker’s Q4 2017 Outlook Report, download the Catalyst Roundup: "A Review of Select Catalysts from Last Quarter’s Outlook Report".

 

This data-rich infographic looks at the results of catalysts for Tenapanor (Ardelyx) for irritable bowel syndrome and Tirasemtiv (Cytokinetics) for amyotrophic lateral sclerosis and is now available to you – for free.

 

2018 Early Outlook Infographic Image

Biomedtracker 2018 Early Outlook Report

What’s on the horizon for pharma in 2018? Find out with Biomedtracker’s Early 2018 Outlook Report extract. Click below to download free extracts from this essential report, which investigates the catalysts expected to occur in the first part of the year for 21 different drugs.

For each drug, the full report contains:

  • Likelihood of phase/PDUFA review success
  • Biomedtracker’s overall Likelihood of Approval (LOA) (based on phase, drug class, and disease group)
  • Results of the catalysts highlighted in Biomedtracker’s Q4 2017 Report
  • A list of Large Impact catalysts through 2018

Early 2018 Outlook Report

Pharma Intelligence latest insights

Data and analysis products

pdpimage

Sitetrove: Clinical trial site & investigator identification

Approximately 400,000 investigators in over 170 countries, all with clinical trial experience, all at your fingertips. Support your trial success and inform your principal investigator (PI) and site selection activities with Sitetrove, now on a sleek, modern interface for simpler, faster and more efficient searching.

Key benefits:

  • Investigator prioritization
  • Epidemiology dashboard
  • Custom tables and charts
pdpimage

Datamonitor Healthcare: data analysis and insight

Datamonitor Healthcare's expert coverage of key diseases, companies, drugs and market trends makes it the go-to product for pharmaceutical and biotechnology companies to support the development and validation of their strategic plans and commercial decisions.

Key benefits:

  • Prioritize market opportunities
  • Identify unmet needs
  • Make informed decisions
pharma projects pharma

Pharmaprojects: track pharma R&D

The industry’s most trusted drug development database, Citeline's Pharmaprojects has been covering pharma R&D across global markets for 35+ years. With 68,000+ drug profiles including 15,000 drugs in active development, it’s the go-to resource for preclinical, clinical, and pipeline coverage, and lifecycle management tracking.

Key benefits:

  • Curated by experts
  • Drug R&D landscape
  • Historical trends

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: